Free · No account

Create your own personal news briefing

A daily PDF of the news that moves your tickers — summaries and market impact, delivered an hour before the open.

Zacks Investment Research

05 Aug 2026, 12:46 UTC · 1h ago

Recursion Pharmaceuticals (RXRX) Reports Q2 Loss, Misses Revenue Estimates

NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.

What the story claims

3 claims · each scored for market impact

What matters in this story

1
Recursion Pharmaceuticals reported quarterly revenues of $7.67 million, missing the Zacks Consensus Estimate by 46.77%. — A significant revenue miss of nearly 47% indicates a severe deterioration in top-line growth and commercial traction.
-0.80
2
Year-over-year revenue for Recursion Pharmaceuticals dropped from $19.22 million to $7.67 million. — A sharp decline in annual revenue suggests a fundamental contraction in the business model or loss of key contracts.
-0.60
3
Recursion Pharmaceuticals reported a quarterly loss of $0.25 per share, missing the consensus estimate of a $0.23 loss. — Missing earnings expectations, even in a loss-making biotech, signals higher-than-expected burn or operational inefficiency.
-0.40

Which stocks this story touches

6 related stories